Literature DB >> 19591938

A genetic variation in the ADORA2A gene modifies age at onset in Huntington's disease.

Claire-Marie Dhaenens1, Sylvie Burnouf, Clémence Simonin, Edwige Van Brussel, Alain Duhamel, Luc Defebvre, Cécile Duru, Isabelle Vuillaume, Cécile Cazeneuve, Perrine Charles, Patrick Maison, Sabrina Debruxelles, Christophe Verny, Hélène Gervais, Jean-Philippe Azulay, Christine Tranchant, Anne-Catherine Bachoud-Levi, Alexandra Dürr, Luc Buée, Pierre Krystkowiak, Bernard Sablonnière, David Blum.   

Abstract

Based on the pathophysiological role of adenosine A(2A) receptors in HD, we have evaluated the association of the 1976C/T single-nucleotide polymorphism in the ADORA2A gene (rs5751876) with residual age at onset (AAO) in HD. The study population consisted of 791 unrelated patients belonging to the Huntington French Speaking Network. The variability in AAO attributable to the CAG repeats number was calculated by linear regression using the log (AAO) as the dependent variable, and the respective rs5751876 genotypes as independent variables. We show that the rs5751876 variant significantly influences the variability in AAO. The R(2) statistic rose slightly but significantly (p=0.019) when rs5751876 T/T genotype was added to the regression model. Patients harbouring T/T genotype have an earlier AAO of 3.8 years as compared to C/C genotype (p=0.02). Our data thus strengthens the pathophysiological role of A(2A) receptors in Huntington's disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19591938     DOI: 10.1016/j.nbd.2009.06.009

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  29 in total

Review 1.  Genetics of caffeine consumption and responses to caffeine.

Authors:  Amy Yang; Abraham A Palmer; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2010-06-09       Impact factor: 4.530

2.  TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease.

Authors:  Ji-Hyun Lee; Jong-Min Lee; Eliana Marisa Ramos; Tammy Gillis; Jayalakshmi S Mysore; Shotaro Kishikawa; Tiffany Hadzi; Audrey E Hendricks; Michael R Hayden; Patrick J Morrison; Martha Nance; Christopher A Ross; Russell L Margolis; Ferdinando Squitieri; Cinzia Gellera; Estrella Gomez-Tortosa; Carmen Ayuso; Oksana Suchowersky; Ronald J Trent; Elizabeth McCusker; Andrea Novelletto; Marina Frontali; Randi Jones; Tetsuo Ashizawa; Samuel Frank; Marie-Helene Saint-Hilaire; Steven M Hersch; Herminia D Rosas; Diane Lucente; Madaline B Harrison; Andrea Zanko; Ruth K Abramson; Karen Marder; Jorge Sequeiros; G Bernhard Landwehrmeyer; Ira Shoulson; Richard H Myers; Marcy E MacDonald; James F Gusella
Journal:  Biochem Biophys Res Commun       Date:  2012-07-03       Impact factor: 3.575

3.  Behavioural profile of Wistar rats with unilateral striatal lesion by quinolinic acid (animal model of Huntington disease) post-injection of apomorphine and exposure to static magnetic field.

Authors:  Carolina Giorgetto; Elaine Cristina Mazzei Silva; Takae Tamy Kitabatake; Guilherme Bertolino; João Eduardo de Araujo
Journal:  Exp Brain Res       Date:  2015-02-11       Impact factor: 1.972

4.  Association of age at onset in Huntington disease with functional promoter variations in NPY and NPY2R.

Authors:  Eugen Kloster; Carsten Saft; Denis A Akkad; Jörg T Epplen; Larissa Arning
Journal:  J Mol Med (Berl)       Date:  2014-02       Impact factor: 4.599

5.  The p. R151C Polymorphism in MC1R Gene Modifies the Age of Onset in Spanish Huntington's Disease Patients.

Authors:  Gemma Tell-Marti; Joan Anton Puig-Butille; Pol Gimenez-Xavier; Ariadna Segu-Roig; Miriam Potrony; Celia Badenas; Victoria Alvarez; José M Millán; María José Trujillo-Tiebas; María A Ramos-Arroyo; Montserrat Milà; Susana Puig
Journal:  Mol Neurobiol       Date:  2016-12-06       Impact factor: 5.590

Review 6.  Advances in the discovery of genetic risk factors for complex forms of neurodegenerative disorders: contemporary approaches, success, challenges and prospects.

Authors:  Sumeet Kumar; Navneesh Yadav; Sanjay Pandey; B K Thelma
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

Review 7.  The Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease.

Authors:  David Blum; Yijuang Chern; Maria Rosaria Domenici; Luc Buée; Chien-Yu Lin; William Rea; Sergi Ferré; Patrizia Popoli
Journal:  J Caffeine Adenosine Res       Date:  2018-06-01

8.  Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington's disease.

Authors:  Izaskun Villar-Menéndez; Marta Blanch; Shiraz Tyebji; Thais Pereira-Veiga; José Luis Albasanz; Mairena Martín; Isidre Ferrer; Esther Pérez-Navarro; Marta Barrachina
Journal:  Neuromolecular Med       Date:  2013-02-06       Impact factor: 3.843

9.  Equilibrative nucleoside transporter ENT1 as a biomarker of Huntington disease.

Authors:  Xavier Guitart; Jordi Bonaventura; William Rea; Marco Orrú; Lucrezia Cellai; Ilaria Dettori; Felicita Pedata; Marc Brugarolas; Antonio Cortés; Vicent Casadó; Ching-Pang Chang; Manikandan Narayanan; Yijuang Chern; Sergi Ferré
Journal:  Neurobiol Dis       Date:  2016-08-24       Impact factor: 5.996

Review 10.  Huntington's Disease: Relationship Between Phenotype and Genotype.

Authors:  Yi-Min Sun; Yan-Bin Zhang; Zhi-Ying Wu
Journal:  Mol Neurobiol       Date:  2016-01-07       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.